Rosetta Genomics' Q1 Loss Nearly Doubles | GenomeWeb
NEW YORK (GenomeWeb News) – Rosetta Genomics today reported that its first-quarter net loss nearly doubled year over year as the firm gears up for initial diagnostic product launches.
 
The Rehovot, Israel-based firm had no revenues for the three-month period ended March 31. The firm expects to have its initial microRNA-based diagnostic tests for cancer approved for use in CLIA labs by the end of this year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.